Mb Caps Capsule
RxNorm Crosswalk NDC 28595-299

View RxNorm Concepts, RxCUIs, and Term Type mappings for this NDC

RxNorm Mapping Clinical Concepts

This drug is included in the RxNorm Current Prescribable Content, a subset of RxNorm that includes all drugs available for prescription in the United States.

The product Mb Caps (NDC 28595-299) is cross-mapped to the RxNorm terminology system to ensure clinical interoperability. This formulation is linked to a unique clinical concept (RxCUI 2637557). By anchoring Allegis Pharmaceuticals, Llc's product data to these standardized identifiers, healthcare systems can maintain accurate medication records, safely automate e-prescribing, and streamline pharmacy workflows.

The following clinical concept cards detail the semantic term types (TTY), prescribable names, and synonymous clinical strings as defined by the National Library of Medicine (NLM).

SCDPrescribable
Featured Concept

hyoscyamine sulfate 0.12 MG / methenamine 120 MG / methylene blue 10.8 MG / phenyl salicylate 36.2 MG / sodium phosphate, monobasic 40.8 MG Oral Capsule
(RxCUI 2637557)

Semantic Clinical Drug

Semantic Clinical Drug: The clinical gold standard representing the Generic Name + Strength + Dosage Form.

Understanding RxNorm Mapping for Mb Caps

RxNorm is a normalized naming system developed by the National Library of Medicine (NLM) to bridge the gap between different drug terminologies. By mapping NDC 28595-299 to RxCUI 2637557, this page provides the standardized "source of truth" required for hospital systems, e-prescribing software, and pharmacy benefit managers (PBMs) to communicate without errors.

Term Type (TTY) Legend for This Page

The clinical cards above utilize specific Term Types (TTY) to define the granularity of the drug concept:

  • PSN Prescribable Name: The standardized name preferred by electronic prescribing (eRx) applications for display.
  • SCD Semantic Clinical Drug: The clinical gold standard representing the Generic Name + Strength + Dosage Form.

* Please review the full disclaimer at the bottom of this page.